Kumagai Shunichi, Nobori Tsutomu
The Center for Rheumatic Diseases, Shinko Hospital, Kobe 651-0072, Japan.
Rinsho Byori. 2013 May;61(5):419-20.
Personalized medicine (PM) is expected to change the healthcare system due to great progress in areas such as pharmacogenomics (PGx) and molecular diagnostics; however, PM is more popular in oncology than in clinic practice. Oncological therapies are easily personalized because accurate diagnostic tests are available to identify patients who can benefit from targeted therapies. Nevertheless, personalized medicine has become a more imminent reality for several reasons, such as the increased awareness of drugs with an adequate benefit/risk ratio to patients, better methods to optimize drug selection and dosing and so on. We invited four speakers to discuss the importance of PGx in the practice of PM from the viewpoint of basic and clinical research.
由于药物基因组学（PGx）和分子诊断等领域取得了巨大进展，个性化医疗（PM）有望改变医疗保健系统；然而，PM在肿瘤学中比在临床实践中更受欢迎。肿瘤治疗很容易实现个性化，因为有准确的诊断测试可用于识别能够从靶向治疗中获益的患者。尽管如此，由于多种原因，如提高了对药物对患者具有适当效益/风险比的认识、优化药物选择和给药的更好方法等，个性化医疗已成为更迫在眉睫的现实。我们邀请了四位演讲者从基础和临床研究的角度讨论PGx在PM实践中的重要性。
